Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Paoloni, Melissa ^a   Webb, Craig ^b   Mazcko, Christina ^a   Cherba, David ^b   Hendricks, William ^c   Lana, Susan ^d   Ehrhart, E J ^d   Charles, Brad ^d   Fehling, Heather ^e   Kumar, Leena ^e   Vail, David ^f   Henson, Michael ^g   Childress, Michael ^h   Kitchell, Barbara ⁱ   Kingsley, Christopher ^c   Kim, Seungchan ^c   Neff, Mark ^b   Davis, Barbara ^c   Khanna, Chand ^a   Trent, Jeffrey ^b,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d Veterinary Dentistry and Oral Surgery   (United States)

^e Clinical Reference Laboratory   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h PURDUE UNIVERSITY   (United States)

ⁱ MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; RNA;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CANCER MODEL; CLINICAL TRIAL; CLUSTER ANALYSIS; COHORT ANALYSIS; DNA SYNTHESIS; DOG DISEASE; DRUG CLASSIFICATION; FEASIBILITY STUDY; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HISTOPATHOLOGY; MALE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PERSONALIZED MEDICINE; PROSPECTIVE STUDY; RNA EXTRACTION; TUMOR BIOPSY; TURNAROUND TIME; WORKFLOW; ANIMAL; BIOLOGY; DISEASE MODEL; DOG; GENETICS; HUMAN; NEOPLASM; PATHOLOGY; PROCEDURES;

ANIMALS; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; DOGS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 84898670884     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090028     Document Type: Article

References (38)

1. Tian Q, Price ND, Hood L (2012) Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 271: 111-121.
2. Zhang L, Yang H, Xu J (2011) Gene expression significance in personalized medicine of non-small-cell lung cancer and gene expression analyzing platforms. Curr Drug Metab 12: 455-459.
3. Xian W, McKeon F (2011) The challenges and hopes of personalized cancer medicine. Genome Med 3: 22.
4. Stricker T, Catenacci DV, Seiwert TY (2011) Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 38: 173-185.
5. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539. (Pubitemid 34534519)
6. McKeage K, Perry CM (2002) Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62: 209-243. (Pubitemid 34169431)
7. Collisson EA, Cho RJ, Gray JW (2012) What are we learning from the cancer genome? Nat Rev Clin Oncol.
8. Roukos DH, Ku CS (2012) Clinical cancer genome and precision medicine. Ann Surg Oncol 19: 3646-3650.
9. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, et al. (2010) Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28: 4877-4883.
10. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, et al. (2012) Personalized Medicine in a Phase I Clinical Trials Program:The MD Anderson Cancer Center Initiative. Clin Cancer Res.
11. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, et al. (2013) Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther 12: 104-116.
12. Jones SJ, Laskin J, Li YY, Griffith OL, An J, et al. (2010) Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol 11: R82.
13. Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, et al. (2012) Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities. J Cell Biochem.
14. Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8: 147-156. (Pubitemid 351161319)
15. Vail DM, MacEwen EG (2000) Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18: 781-792.
16. Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, et al. (2006) The dog as a cancer model. Nat Biotechnol 24: 1065-1066.
17. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, et al. (2005) Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438: 803-819. (Pubitemid 41753059)
18. Vail D (2011) Veterinary Co-operative Oncology Group -Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Veterinary and Comparative Oncology 10: 1-30.
19. Saulnier Sholler GL, Ferguson W, Bergendahl G, Currier E, Lenox SR, et al. (2012) A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Journal of Cancer Therapy 3: pp. 602-612.
20. Briggs J, Paoloni M, Chen QR, Wen X, Khan J, et al. (2011) A compendium of canine normal tissue gene expression. PLoS One 6: e17107.
21. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, et al. (2009) Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 4: e4972.
22. Monks NR, Cherba DM, Kamerling SG, Simpson H, Rusk AW, et al. (2013) A multi-site feasibility study for personalized medicine in canines with Osteosarcoma. Journal of translational medicine 11: 158.
23. Andrechek ER, Nevins JR (2010) Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med (Berl) 88: 1095-1100.
24. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, et al. (2009) Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC genomics 10: 625.
25. Richards KL, Motsinger-Reif AA, Chen H-w, Fedoriw Y, Fan C, et al. (2013) Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Research.
26. Ofiara LM, Navasakulpong A, Ezer N, Gonzalez AV (2012) The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment. Curr Oncol 19: S16-23.
27. Beijnen JH, Schellens JH (2010) Personalized medicine in oncology: a personal view with myths and facts. Curr Clin Pharmacol 5: 141-147.
28. Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, et al. (2011) How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. Health Aff (Millwood) 30: 2259-2268.
29. Paoloni MC, Mazcko C, Fox E, Fan T, Lana S, et al. (2010) Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 5: e11013.
30. NCI, NCI-Bioinformatics, Oracle (2002 Fall -[current version 2007 Jan; cited 2008 June]) Cancer Central Clinical Database (C3D) [Internet]. Version 4.5.2.
31. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nature reviews Drug discovery 5: 993-996. (Pubitemid 44835126)
32. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39: D1035-1041.
33. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935. (Pubitemid 44497995)
34. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, et al. (2007) Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 67: 3171-3176. (Pubitemid 46724854)
35. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, et al. (2007) A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 104: 13086-13091. (Pubitemid 351737597)
36. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, et al. (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad SciUS A 98: 10787-10792. (Pubitemid 32878698)
37. Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, et al. (2009) Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther 8: 2386-2395.
38. Dezso Z, Nikolsky Y, Nikolskaya T, Miller J, Cherba D, et al. (2009) Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol 3: 36.